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THE EXACT-PRO INITIATIVE: DEVELOPMENT AND
VALIDATION OF A SINGLE PATIENT-REPORTED OUTCOME
MEASURE FOR EVALUATING EXACERBATIONS OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
Leidy NK,Wilcox TK, Roberts L,Winnette RM, Murray L
United BioSource Corporation, Bethesda, MD, USA
OBJECTIVES: To develop and validate a patient-reported
outcome (PRO) instrument for measuring frequency, severity,
and duration of COPD exacerbations in international trials.
METHODS: Multi-sponsor initiative involving experts and the
FDA. Phase I: Instrument development informed by literature
and qualitative data from focus groups and interviews with U.S.
COPD patients. International experts addressed concept rel-
evance, transferability, translation ease. Phase II: Prospective,
2-group, observational study of patients with 1) conﬁrmed exac-
erbation (PDA diary Days 1–28 and 60–67) or 2) stable COPD
(PDA for 7 days). Item analyses and Rasch IRT were used to
reduce the items from 23 to 14. Validity testing included known-
group differences and relationship to clinical history, SGRQ-C,
and clinician and patient assessment of exacerbation severity.
RESULTS: Phase I: N = 83; 45% male; 16% African American;
13% Hispanic; mean age = 65 (10); stable FEV-1 = 44% pred
(16). Phase II: N 410 (222 acute; 188 stable); 48% male; mean
age = 65 (10); stable FEV-1 = 51% pred (20). Factor analyses
supported a unidimensional structure suitable for Rasch analysis.
Overall chi-square = 149.3 df = 84; person-separation index =
0.92. Three respiratory domains (breathlessness (5 items), cough-
sputum (2 items), chest symptoms (3 items)) account for 68% of
the variance; 4 items address systemic manifestations. Internal
consistency (Day 1, N = 410) total = 0.91; domains = 0.87; 0.69;
0.87. Reproducibility (ICC) in stable patients (n = 171) Day 1 to
7 = 0.77; 0.71; 0.65; 0.64. Correlation with SGRQ-C Day 1
(N = 395): r = 0.64; 0.66; 0.35; 0.46 (p < 0.0001). Signiﬁcant
differences in scores were found across exacerbation severity Day
1 (p < 0.001) and between responders and non-responders Days
1 to 10 (p < 0.0001). CONCLUSIONS: The EXAcerbations of
Chronic Pulmonary Disease Tool (EXACT) is a 14-item diary for
evaluating exacerbation outcomes of COPD with measurement
properties demonstrated to be adequate for use in clinical trials
with a similar population.
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INTERPRETING SCORES ONTHREE PATIENT-REPORTED
OUTCOME MEASURES FOR ASTHMA
Meads DM1,Twiss J1, McKenna SP1, Revicki D2, Pokrzywinski R3,
Gale R4
1Galen Research, Manchester, UK, 2United BioSource Corporation,
Bethesda, MD, USA, 3United Biosource Corporation, Pittsburgh, PA,
USA, 4Novartis AG, Horsham, UK
OBJECTIVES: To aid interpretation of scores on the Asthma
Life Impact Scale (ALIS; scored 0–22), COPD and Asthma Sleep
Impact Scale (CASIS; scored 0–100) and COPD and Asthma
Fatigue Scale (CAFS; scored 0–100). These new patient reported
outcome measures, designed for use in clinical trials, have pre-
viously been shown to be reliable and valid. METHODS: Ques-
tionnaire data from UK (n = 140; 29.3% male; mean age = 50.6
years) and US (n = 185; 25.9% male; mean age = 46.0 years)
surveys were analysed. Mean questionnaire scores were evalu-
ated against clinician severity rating and by exacerbation status
(US only). Effect sizes (ES) and standard errors of measurement
(SEM) gave a preliminary estimate of the minimal important
difference (MID). RESULTS: Scores on all three measures were
signiﬁcantly related to clinician rating of asthma severity
(p < 0.001) and patients who had had an exacerbation in the
previous week had signiﬁcantly (p < 0.05) worse scores on all
measures. For the ALIS the values for 0.3 ES, 0.5 ES and SEM
were 1.9, 3.2 and 1.7 respectively. For the CASIS the ﬁgures
were 5.3, 8.8 and 5.2 and for the CAFS; 7.2, 12.0 and 5.4.
Therefore these distribution-based analyses suggest that the
MID is in the region of two for the ALIS, ﬁve for the CASIS,
and seven for the CAFS. CONCLUSIONS: The analyses pro-
vide preliminary information on how to interpret scores on the
scales. Further analyses of longitudinal data are required
to conﬁrm these ﬁndings, to assess anchor-based estimates
and to allow greater precision in powering studies using these
questionnaires.
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HAS ASTHMA CONTROL IMPROVED SINCE AIRE? RESULTS
OF A SURVEY IN 5 EUROPEAN COUNTRIES
Gueron B1, Freedman D2,Annunziata K2, Poterre M1
1GSK, Marly le Roi, France, 2Consumer Health Sciences, Princeton, NJ,
USA
OBJECTIVES: According to the GINA guidelines, asthma
control can be achieved and maintained in a majority of patients.
The 1999 AIRE study showed that only 5% of the adult asth-
matic patients were controlled. Several years later, how does
the situation look like? METHODS: Population based cross-
sectional survey was carried out in 2006 in France, Germany,
Italy, Spain, and the UK. A detailed questionnaire was adminis-
tered to a sample of adult individuals drawn from an Internet
panel. The Asthma Control Test (ACTTM) was used to assess the
level of control: Total Control (TC, score = 25), Well controlled
(WC, score = 20–24) and not well-controlled (NWC, score <20).
RESULTS: Among the 37,476 individuals who participated,
2,337 had been diagnosed with asthma by a physician. 80% used
rescue medication 2–3 times a week, 58% woke up once a week
due to asthma, 70% had shortness of breath 3–6 times /week.
Overall, 55% of asthmatic patients were not controlled despite
being treated, ranging from 45% to 72%. CONCLUSIONS:
This survey suggests the level of asthma control has improved
since AIRE. However, the majority of patients still remain uncon-
trolled. Further efforts are required to translate the GINA rec-
ommendations to prevent symptoms and ensure patients achieve
and maintain control into reality.
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SOCIOECONOMIC ANALYSIS OF SMOKER’S PROFILE WHO
INTENDSTO QUIT
Ramón JM1, Bruguera E2, Sanz de Burgoa V3, Ramírez E4
1Hospital de Bellvitge, Barcelona, Spain, 2Hospital Vall d’Hebron,
Barcelona, Spain, 3Laboratorios Pﬁzer, Alcobendas, Madrid, Spain,
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OBJECTIVES: Depressed socio-cultural and economic groups
tend to smoke more than the others. We aimed to determine
socioeconomic level related aspects of the smoker’s proﬁle who
intends to stop smoking. METHODS: A total of 1634 smokers
older than 18, attended by General Practitioners and Specialized
Physicians in Spain, were included in a multicentric cross-
sectional survey study performed in February–June 2007. After
being asked about their intention of smoking cessation, all of
them were determined to or had taken some action to quit
smoking within the previous 15 days. Socio-demographic data,
taking into account socio-economic indicators, history of
smoking and reasons to stop smoking were collected. Descriptive
statistical analysis was performed. RESULTS: The analysed
population included 1618 subjects from 167 centers fulﬁlling all
the selection criteria. Their mean age was 45.6  12.0 and 56%
were men. The majority (67.8%) had studied beyond high school
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and most of them (76.0%) were active workers. Daily mean
cigarette consumption during working days was 20.7  9.9.
Mean annual expenses for cigarettes reached €961.5  442.3
and the median expense was €876, although signiﬁcant differ-
ences (p < 0.0001) within gender, age groups, educational level,
work situation and geographic area were observed. Men older
than 46–65 years showed the highest expense, regardless of their
income; and unemployed workers spent more than active
workers on tobacco. A mean annual expense for cigarettes higher
than 1500 € was associated with a higher use of smoking cessa-
tion treatments (p = 0.0009). However, less than 0.9% of
smokers wanted to stop smoking due to economic reasons.
CONCLUSIONS: Smokers who want to quit smoking spend
annually a mean of €961.5 (median of €876) on cigarettes,
although there are signiﬁcant differences within socio-
demographic proﬁles. The higher the expenses for cigarettes are,
the higher the expenses for smoking cessation treatments reach.
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HOW CONGRUENT ARE PATIENT AND CLINICIAN MODELS
OF ASTHMA CONTROL?—PRELIMINARY FINDINGS FROM A
QUALITATIVE STUDY
Ruedell K1, Bonner N2,Arbuckle R2,Abetz L3, Hareendran A4,
Gilbert C4
1Pﬁzer Ltd, Sandwich, UK, 2Mapi Values Ltd, Bollington, UK, 3Mapi
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OBJECTIVES: Recent regulatory guidelines emphasize the
importance of patient input in the development of patient
reported outcome (PRO) measures that will be used as clinical
trial endpoints to support labelling claims. In asthma prevention
and management, consensus among clinicians is growing regard-
ing models of asthma control. It is uncertain how closely patient
models concur with clinical perspectives of asthma control. The
objective of this research was to develop a conceptual model of
asthma control based on both patient and clinician input and
explore the congruence of patient and clinical perspectives.
METHODS: Fifty-ﬁve patients discussed the concept of asthma
control in 8 focus groups (2 each in France, Germany, UK & US).
Independently two asthma specialists and two general practitio-
ners were interviewed in each country (18 in total) about their
understanding of asthma control, symptoms and treatments.
Data was analyzed using thematic analysis techniques based on
grounded theory, and conceptual models were developed for
patient and clinician perspectives. RESULTS: When asked what
asthma control meant to them, patients talked about symptoms,
sleep disturbance, tiredness, rescue medication use, activity limi-
tations, the experience of asthma attacks and experiencing panic
and fear. Clinicians focussed primarily on presence and severity
of symptoms and medication use, but also mentioned the ability
of the patient to remain active, patients’ hospitalisation, and
satisfaction with and adherence to medication as being indicators
of asthma control. CONCLUSIONS: Our research suggests that
patient and clinician models are complementary, but not com-
pletely consistent. Both emphasize symptom control and rescue
medication use as key indicators. Patients, however, also consider
emotional responses, tiredness and activity limitations as impor-
tant, whereas clinicians more often considered adherence and
health care utilisation. Differences in the models support the
importance of including both patient and clinical perspectives
when developing PRO measures for clinical trials.
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A SURVEY OFTHE BURDEN OF ALLERGIC RHINITIS
IN EUROPE
Gueron B1, Canonica GW2, Bousquet J3, Mullol J4, Scadding G5,
Virchow JC6
1GSK, Marly le Roi, France, 2University of Genova, Genova, Liguria,
Italy, 3INSERM, Montpellier, MT, France, 4Institut D’investigacions
Biomediques August Pi I Sunyer, Barcelona, Spain, 5Royal National
Throat, Nose and Ear Hospital, London, UK, 6Universitatsklinik
Rostock, Rostock, Germany
OBJECTIVES: The perceptions of patients and physicians re-
garding the symptoms and impact of allergic rhinitis (AR) were
assessed in a prospective, international, cross-sectional survey
using a convenience sample of consulting patients. We present the
combined survey results from Germany, France, Italy, Spain and
UK. METHODS: Data were recorded by 1482 patients and
matched with records completed by primary care physicians
and specialists. Diagnostic tests to conﬁrm AR had been per-
formed on 1279 (86.3%) patients. Both physicians and patients
recorded the presence, severity and impact of symptoms. Health-
related quality of life (HRQoL) was assessed. RESULTS: A large
proportion of patients had moderate–severe disease (67.2%;
n = 996), persistent disease (42.5%; n = 630) and co-morbidities
such as asthma (31.5%; n = 467). Patients generally rated their
disease as more severe than did their physicians (P < 0.001). At
the time of the consultation, one-third of all patients reported
that their current nasal and ocular symptoms were moderate or
severe in nature. According to the physicians’ assessment, good
control of nasal and ocular symptoms was achieved in 45.4%
(n = 673) and 51.3% (n = 760) of patients, respectively. Overall,
43.3% (n = 641) of those surveyed were using two or more
medicines for their AR. HRQoL was correlated with disease
severity and with the number of days without symptoms in the
previous 4 weeks. AR had a signiﬁcantly greater impact in
patients with more persistent disease than in those with intermit-
tent disease (2.3  1.3 vs. 1.9  1.2; P < 0.001). Nonetheless,
81.8% (n = 601) of patients with intermittent disease reported
some impairment of their daily life as a result of their AR.
CONCLUSIONS: AR remains a signiﬁcant health problem
because of the high burden of symptoms and its impact on
general well being and HRQoL.
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SYMPTOMS AND IMPACT OF SYMPTOMS AS REPORTED BY
ASTHMA PATIENTS
Williams AE1, Jacques L1, Rofail D2, Heelis R2
1GlaxoSmithKline R&D, Uxbridge, UK, 2Mapi Values, Bollington,
Cheshire, UK
OBJECTIVES: Shortness of breath, chest tightness, wheeze and
cough are hallmark symptoms of asthma. These can signiﬁcantly
impact a patient’s life causing impairment to a patient’s physical,
emotional and social wellbeing. To evaluate a treatment’s efﬁ-
cacy, it is important to assess endpoints that are important to
patients. This study aimed to conﬁrm symptoms and their impact
which are important to asthma patients. METHODS: Fifteen
patients with asthma, meeting predeﬁned inclusion criteria were
recruited by MAPI Values in Boston, USA. All patients con-
sented. The semi-structured interviews explored symptoms and
impact of symptoms. Patients also completed the Asthma
Control TestTM (ACT) and the Asthma Quality of Life Question-
naire (AQLQ(S)). Taped interviews were transcribed maintaining
anonyminity and analysed to answer the key questions in the
interview guide. Findings of the ﬁrst 11 (75%) interviews were
compared with the ﬁnal 4 (25%) interviews to determine the
level of consistency in the pattern of responses. RESULTS: All
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